相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温,避光
- 克隆性:
单克隆
- 抗体名:
IL-1R2 / CD121b抗体
Antibody Type : Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
克隆号 : 7H4D4F8
抗体宿主 : Mouse IgG1
缓冲液 : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
制备方法 : This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-1R2 / CD121b (rh IL-1R2 / CD121b; Catalog#10111-H08H; NP_004624.1; Met 1-Glu 343). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
IL-1R2 / CD121b抗体 Background
The pleiotropic cytokine IL1 is produced to regulate development and maintenance of the inflammatory responses, and binds to specific plasma membrane receptors on cells. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). A closely related receptor-like chain IL1R accessory protein (IL1RAcP) has been reported to heterodimerize with the IL1RI to form the signal transduction complex which appears to mediate all the known IL1 signal processes. IL1RII structurally consisting of a ligand binding portion comprised of three Ig -like domains, a single transmembrane region, and a short cytoplasmic domain, is expressed in a variety of cell types including B lymphocytes, neutrophils, monocytes, large granular leukocytes and endothelial cells. Like the IL1RI, the human IL1RII can bind all three forms of IL1 (IL1 alpha, IL1 beta and IL1ra) but does not transmit IL1 signals. In addition to the membrane-bound form, IL1RII also exists as the soluble form, and either acts as a decoy receptor that inhibits IL1 action by blocking the binding of IL1 to the type I receptor complex. Furthermore, IL4 is reported to antagonize the activity of IL1 by inducing the expression and release of this cytokine. Recombinant soluble IL1RII is thus a potent antagonist of IL1 action, and serves as a potential therapeutic target.
IL-1R2 / CD121b抗体相关产品如下:xy-0130R SARS S-protein抗冠状病毒表面S蛋白抗体
xy-0121R SYAP1突触素抗体/突触相关蛋白-1
xy-0088R Secretin分泌素抗体
xy-0444R Slc22A17可溶性载质转运蛋白22A17抗体
xy-1730R phospho-Src(Tyr529)磷酸化Src原癌基因抗体
xy-3567R SHIP1SH2结构含磷酸肌醇SHIP1抗体
xy-1684R SKIC-SKI抗体
xy-3397R Phospho-SGK1 (Thr256)磷酸化糖皮质激素调节激酶1抗体
xy-3390R Phospho-SATB1 (Ser47)磷酸化核基质结合区结合蛋白1抗体
xy-3395R Phospho-SGK1 (Ser78)磷酸化糖皮质激素调节激酶1抗体
xy-3396R Phospho-SGK1 (Ser422)磷酸化糖皮质激素调节激酶1抗体
xy-1303R SFRP1分泌型卷曲相关蛋白1抗体
xy-4905R SORBS2精氨酸结合蛋白2抗体
xy-8717R SLC30A3溶质载体锌转运3抗体
xy-8324R SERPINB13丝氨酸蛋白酶抑制剂13抗体
xy-8330R STK25丝氨酸/苏氨酸激酶25抗体
xy-7879R SUPT16H染色体特异性转录延伸因子抗体
xy-11863R KIAA1598阅读障碍相关蛋白Shootin抗体
xy-7732R Separase外纺锤体极样蛋白1抗体
xy-3667R SLC44A1溶质转运蛋白家族44成员1抗体
xy-10085R SLC7A9离子转运相关蛋白SLC7A9抗体
xy-8610R SLC20A2溶质载体蛋白家族20成员2抗体
xy-10098R S100A6S100钙结合蛋白A6抗体
xy-12364R SCXA碱性螺旋-环-螺旋转录因子SCXA抗体
xy-12346R Stabilin 2清道夫受体STAB2抗体
xy-12351R STRA6维甲酸诱导蛋白6抗体
xy-10200R Sclerostin骨形态发生抑制蛋白SOST抗体
xy-10367R Sarcomeric Alpha Actininα横纹肌辅肌动蛋白/α-SCA抗体
xy-12317R SCUBE3新型分泌细胞表面蛋白/成骨细胞相关蛋白SCUBE3抗体
xy-12318R SCUBE2内皮分泌蛋白SCUBE2抗体
xy-7120R Sulfite oxidase亚硫酸盐氧化酶抗体
xy-8877R Somatostatin生长抑素抗体
xy-10315R phospho-Syntaxin 1a(Ser188)磷酸化突触融合蛋白1抗体
xy-3787R SCD1固醇酰辅酶A脱氢酶1抗体
xy-6015R SNF2L解旋酶SNF2L抗体
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验(杨希峰),Yang CY(杨春瑛) et al. Generation and characterization of monoclonal antibody against HIT3a (抗CD3单克隆抗体HIT3a的制备和特异性鉴定), Acta Academiae Medicinae Sinicae (中国医学科学院学报),1993, 15:157-162.[6] Xiong D S(熊冬生),Yang C Z(杨纯正),Shao X F(邵晓枫)et al. Generation
因为抗体的结合而减少;在人体血清中无游离的CD20存在;最重要的是B淋巴细胞瘤上的CD20少有内吞和脱落的发生[ 2-5 ] 。1997年,以CD20为靶点的嵌合抗CD20单克隆抗体Rituxan已获准应用于B细胞淋巴瘤的治疗[ 6 ]。HI47(IgG3)是我所于1990年研制成功的国内第一个抗CD20鼠源性单克窿抗体,第四届国际人类白细胞分化抗原会议将HI47命名为CD20+X[ 7 ] 。我们利用噬菌体显示技术从HI47杂交瘤细胞中克隆到抗CD20抗体HI47可变区基因,将该基因构建成为嵌合的抗
20B淋巴细胞表面的膜蛋白CD20对B淋巴细胞的增殖和分化具有调节作用[1]。由于CD20分子仅在前-B淋巴细胞、未成熟B淋巴细胞、成熟B淋巴细胞、激活B淋巴细胞中表达,而在浆细胞、淋巴多能干细胞以及其它组织均无CD20的表达[2,3,4],在人体血清中亦无游离CD20的存在[5],因此CD20可作为B淋巴细胞瘤治疗的一个理想治疗靶点。限制抗体临床使用的因素主要有抗体产生的免疫原性和抗体的生产能力是否能够满足临床需要。第四届国际人类白细胞分化抗原会议将鼠源性单克隆抗CD20抗体HI47(IgG3)正式命名为CD20+X
技术资料暂无技术资料 索取技术资料





